In a report released today, Mayank Mamtani from B.Riley Financial reiterated a Buy rating on Novavax (NVAX – Research Report), with a price target of $181.00. The company’s shares closed last Monday at $51.40, close to its 52-week low of $41.33.
According to TipRanks.com, Mamtani is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -31.7% and a 20.7% success rate. Mamtani covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Madrigal Pharmaceuticals, and Spectrum Pharmaceuticals.
Novavax has an analyst consensus of Moderate Buy, with a price target consensus of $135.00, a 154.7% upside from current levels. In a report issued on May 15, Jefferies also reiterated a Buy rating on the stock with a $190.00 price target.
The company has a one-year high of $277.80 and a one-year low of $41.33. Currently, Novavax has an average volume of 4.68M.
Based on the recent corporate insider activity of 64 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of NVAX in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Novavax, Inc. is a late-stage biotechnology company, which focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It produces vaccine candidates to respond to both known and emerging disease threats by using the proprietary recombinant nanoparticle vaccine technology. Its vaccine candidates include ResVax and NanoFlu. It also develops immune stimulating saponin-based adjuvants through its wholly owned Swedish subsidiary, Novavax AB. The company was founded in 1987 and is headquartered in Gaithersburg, MD.
Read More on NVAX:
- Analysts Offer Insights on Technology Companies: Lattice Semiconductor (LSCC) and Snap (SNAP)
- Brookline Capital Markets Thinks MEI Pharma’s Stock is Going to Recover
- Top Insider Laps up TransDigm Shares Worth $26M
- Bank Hapoalim’s Q1 Results, Future Plans Impressive
- Liquidia Technologies (LQDA) Gets a Hold Rating from Wedbush